Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma

Urology Case Reports

Andres Matoso¹  Taylor P. Kohn²  Matthew J. Rabinowitz²  Vanessa N. Peña²  Iryna V. Samarska³  Amin S. Herati³ 

[1] Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

关键词: Infertility;    Male;    Azoospermia;    BRAF;    immune Checkpoint inhibitor therapy;    Immunotherapy;   

DOI  :  

来源: DOAJ

【 摘 要 】

Azoospermia is classified as the complete absence of sperm in ejaculate and accounts for 10–15% of male infertility. Many anticancer drugs are known to cause defects in spermatogenesis, but the effects of immune checkpoint inhibitor cancer therapy on spermatogenesis remains largely unknown. Presented here is a normozoospermic man (60 million sperm/cc of ejaculate) who received a trial combination treatment of Ipilimumab/Nivolumab to treat BRAF negative, stage IV metastatic melanoma. Two years after the treatment, the patient presented as completely azoospermic. The patient subsequently underwent microdissection testicular sperm extraction, during which no sperm was retrieved, and sertoli-only pathology was elucidated.

【 授权许可】

Unknown